Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
Status:
Completed
Trial end date:
2021-05-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether nab-Paclitaxel (Abraxane®) and ramucirumab
(Cyramza®) are effective when used in combination for treating patients with metastatic
gastroesophageal cancer who have either progressed or not responded to prior therapy.